Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Bamlanivimab/convalescent-anti-SARS-CoV-2-plasma

Drug resistance: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bronstein Y, et al. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. Journal of Medical Virology 94: 1241-1245, No. 3, Mar 2022. Available from: URL: http://doi.org/10.1002/jmv.27445 Bronstein Y, et al. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. Journal of Medical Virology 94: 1241-1245, No. 3, Mar 2022. Available from: URL: http://​doi.​org/​10.​1002/​jmv.​27445
Metadaten
Titel
Bamlanivimab/convalescent-anti-SARS-CoV-2-plasma
Drug resistance: 2 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30444-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Riboflavin

Case report

Multiple drugs